Readystate Asset Management LP Abb Vie Inc. Call Options Transaction History

Readystate Asset Management LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $8.31 Million - $9.71 Million	-53,700 Reduced 94.21%	3,300 $566 Million
Q1 2024 May 10, 2024	BUY	$159.82 - $182.1 $8.02 Million - $9.14 Million	50,200 Added 738.24%	57,000 $10.4 Billion
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $935,680 - $1.05 Million	6,800 New	6,800 $1.05 Billion
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $289,220 - $333,080	2,000 New	2,000 $319 Million

3,767

1.28B

13M

9.83M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $360B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Readystate Asset Management LP with notifications on news.